FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes.
Asmerom Tesfamariam SengalAnn-Marie PatchCameron E SnellDeborah S SmithSamuel C Y LeungAline TalhoukElizabeth D WilliamsJessica Nell McAlpinePamela M PollockPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
FGFR2c expression appears an independent prognostic biomarker in patients with EEC and further discerns the outcomes within grade 3 tumors, ESMO high-risk groups, as well as within the MMRd and p53wt subtypes. FGFR2c inclusion into future molecular subtyping can further refine risk stratification of EEC.